动态增强磁共振成像在抗肿瘤血管药物早期临床试验中的应用  

The application of dynamic contrast-enhanced magnetic resonance imaging in early-phase clinical trials of antivascular medicine for malignant tumors

作　　者：李骁扬[1] 田野[1] 

机构地区：[1]苏州大学附属第二医院放疗科,215004

出　　处：《国际放射医学核医学杂志》2014年第5期309-314,共6页International Journal of Radiation Medicine and Nuclear Medicine

基　　金：国家自然科学基金（81172128,81372411）

摘　　要：动态增强磁共振成像（DCE-MRI）正逐渐被应用于抗肿瘤血管药物的早期临床试验。该文将对传统临床试验药效评价体系应用于抗肿瘤血管分子靶向药物研发中所存在的问题、DCE-MRI的相应技术原理、DCE-MRI临床应用现状与其在临床试验中的优势、存在的问题与展望做一综述，并列举一些近年来应用DCE-MRI技术进行抗肿瘤血管分子靶向药物临床试验的典型案例。The development and research of antivascular medicine has already exerted challenges for traditional clinical trials and its evaluation system. Dynamic contrast-enhanced magnetic resonance imaging （DCE-MRI）, as an uninvasive method to visualize and assess vascular structure and function, has been gradually utilized in clinical trials of antivascular medicine and improving stepwise with a view to further detecting angiogenesis of tumor and effects of medicine. This review will articulate on defects of traditional evaluation system in clinical trials of antivascular medicine, technological characteristics of DCE-MRI as well as pros and cons of its application in clinical trials. The detailed utilization of DCE-MRI in some early phase clinical trials during recent years will also be orchestrated in this review.

关 键 词：磁共振成像 动态增强 肿瘤 抗血管治疗 药物评价 

分 类 号：R730.5[医药卫生—肿瘤] R445.2[医药卫生—临床医学]